Myeloproliferative Neoplasms

Top Story

Study challenges ‘default use of hypomethylating agents’ in high-risk myelodysplastic syndrome

Study challenges ‘default use of hypomethylating agents’ in high-risk myelodysplastic syndrome
November 15, 2019
In the Journals

Oral blood cancer drug may worsen cardiometabolic health

November 13, 2019
An oral chemotherapy treatment used to treat myeloproliferative neoplasms is associated with substantial weight gain and increased systolic blood pressure, according to…
In the JournalsPerspective

Symptom burden a key component of disease control assessment in polycythemia vera

November 8, 2019
Patients with polycythemia vera can experience high symptom burden even if their blood counts are controlled, according to an analysis from the prospective…
FDA News

FDA restructures, renames office that reviews cancer therapies

November 6, 2019
The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s Office of Oncologic…
More Headlines »
CME ABIM MOC

Ace the Case: A 65-Year-Old Female With Cough and Shortness of Breath

There is no commercial support for this activity.

Ace the Case: A 65-Year-Old Female With Cough and Shortness of Breath
More »
Video
Meeting News

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
More »
CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »